Sanjiv Patel - 27 Jan 2022 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
President and CEO, Director
Signature
/s/ Brian Adams, as Attorney-in-Fact
Issuer symbol
RLAY
Transactions as of
27 Jan 2022
Net transactions value
$0
Form type
4
Filing time
31 Jan 2022, 16:25:11 UTC
Previous filing
07 Jan 2022
Next filing
14 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Award $0 +527,140 $0.000000 527,140 27 Jan 2022 Common Stock 527,140 $20.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date.